Welcome to our dedicated page for Insulet SEC filings (Ticker: PODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating pod shipment data, FDA update timelines, or reimbursement risk disclosures inside Insulet鈥檚 multi-hundred-page reports can feel overwhelming. If you have ever searched for 鈥淚nsulet SEC filings explained simply鈥� or wondered how to decode 鈥淚nsulet insider trading Form 4 transactions,鈥� you are not alone. Medical-device accounting, clinical milestones, and supply-chain details are scattered across 10-K, 10-Q, 8-K, and proxy statements, making analysis time-consuming.
Stock Titan solves that problem. Our AI-powered engine parses every new document the moment it hits EDGAR, then delivers concise, plain-English summaries. Need the latest 鈥淚nsulet quarterly earnings report 10-Q filing鈥� without wading through footnotes? Curious about real-time 鈥淚nsulet Form 4 insider transactions鈥� before a material announcement? Want the 鈥淚nsulet annual report 10-K simplified鈥� so you can focus on Omnipod margin trends instead of arcane accounting language? We map each section, flag material events from 8-K filings, and highlight changes in executive stock ownership鈥攁ll in one place.
Here is how professionals use the page:
- Track 鈥淚nsulet executive stock transactions Form 4鈥� within minutes of submission
- Compare pod sales growth by segment using our 鈥淚nsulet earnings report filing analysis鈥�
- Review 鈥淚nsulet proxy statement executive compensation鈥� without sifting through appendices
- See 鈥淚nsulet 8-K material events explained鈥� in context of FDA approvals or supply-chain shifts
- Answer complex questions like 鈥渦nderstanding Insulet SEC documents with AI鈥� in seconds
Whether you monitor insider buying, evaluate clinical trial spending, or model recurring pod revenue, Stock Titan鈥檚 real-time alerts, AI summaries, and complete coverage ensure you never miss a disclosure that matters.
Capital Research Global Investors reports beneficial ownership of 4,736,127 shares of Insulet Corporation, equal to 6.7% of the company's outstanding common stock. The filing shows sole voting power for 4,730,490 shares and sole dispositive power for 4,736,127 shares, with no shared voting or dispositive authority reported.
The statement classifies the filer as an investment adviser and includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. This is a routine institutional ownership disclosure reflecting a material passive stake above the 5% threshold.
Insulet Corporation insider report: Prem Singh, SVP, Global Operations, reported multiple equity transactions dated 08/07/2025 involving common stock and stock options of Insulet (PODD). The Form 4 shows two acquisitions of common stock for 585 shares at $264.69 and 758 shares at $276.36, and a disposition of 1,343 shares sold at $320. The filing states these transactions were effected under an existing Rule 10b5-1 trading plan. The report also discloses annual non-qualified stock option awards: 585 options at a $264.69 exercise price (expiring 02/28/2032) and 758 options at a $276.36 exercise price (expiring 02/28/2033), each vesting in substantially equal installments over four years. The document lists line-by-line beneficial ownership figures corresponding to each transaction.
FAQ
What is the current stock price of Insulet (PODD)?
What is the market cap of Insulet (PODD)?
